Expression of the immune regulation antigen CD70 in osteosarcoma

Cancer Cell International

Arjan C Lankester³  Marco W Schilham³  Judith VMG Boveé²  R Maarten Egeler⁵  Annemarie Cleton-Jansen²  Karoly Szuhai⁴  Laurens GL Sand²  Gerharda H Boerman³  Marieke L Kuijjer²  Susy J Santos³  Jens HW Pahl¹ 

[1] Innate Immunity Group, German Cancer Research Center, Heidelberg, 69120, Germany;Department of Pathology, Leiden University Medical Center, Leiden, 2333ZA, The Netherlands;Department of Pediatrics, Leiden University Medical Center, Leiden, 2333ZA, The Netherlands;Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, 2333ZA, The Netherlands;Division of Hematology/Oncology, Hospital for Sick Children/University of Toronto, Toronto, M5G1X8, Canada

关键词: CD27;    Immunotherapy;    Osteosarcoma;    CD70;   

Others  :  1138455
DOI  :  10.1186/s12935-015-0181-5

 received in 2014-05-02, accepted in 2015-03-03,  发布年份 2015

【 摘 要 】

Osteosarcoma is the most frequent bone cancer in children and young adults. The outcome of patients with advanced disease is dismal. Exploitation of tumor-immune cell interactions may provide novel therapeutic approaches. CD70-CD27 interactions are important for the regulation of adaptive immunity. CD70 expression has been reported in some solid cancers and implicated in tumor escape from immunosurveillance. In this study, expression of CD70 and CD27 was analyzed in osteosarcoma cell lines and tumor specimens.

CD70 protein was expressed on most osteosarcoma cell lines (5/7) and patient-derived primary osteosarcoma cultures (4/6) as measured by flow cytometry. In contrast, CD70 was detected on few Ewing sarcoma cell lines (5/15) and was virtually absent from neuroblastoma (1/7) and rhabdomyosarcoma cell lines (0/5). CD70⁺ primary cultures were derived from CD70⁺ osteosarcoma lesions. CD70 expression in osteosarcoma cryosections was heterogeneous, restricted to tumor cells and not attributed to infiltrating CD3⁺ T cells as assessed by immunohistochemistry/immunofluorescence. CD70 was detected in primary (1/5) but also recurrent (2/4) and metastatic (1/3) tumors. CD27, the receptor for CD70, was neither detected on tumor cells nor on T cells in CD70⁺ or CD70⁻ tumors, suggesting that CD70 on tumor cells is not involved in CD27-dependent tumor-immune cell interactions in osteosarcoma. CD70 gene expression in diagnostic biopsies of osteosarcoma patients did not correlate with the occurrence of metastasis and survival (n = 70).

Our data illustrate that CD70 is expressed in a subset of osteosarcoma patients. In patients with CD70⁺ tumors, CD70 may represent a novel candidate for antibody-based targeted immunotherapy.

【 授权许可】

   
2015 Pahl et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010, 15:615-34.
• [2]Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al.: Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011, 17:2110-9.
• [3]van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ: Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992, 67:166-74.
• [4]Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA: Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009, 229:216-31.
• [5]Borst J, Hendriks J, Xiao Y: CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005, 17:275-81.
• [6]Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, et al.: Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006, 66:2328-37.
• [7]Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, et al.: CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006, 95:298-306.
• [8]Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, et al.: CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol 2008, 180:3739-45.
• [9]Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, van Lier RA: Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994, 152:1762-73.
• [10]Hashimoto-Okada M, Kitawaki T, Kadowaki N, Iwata S, Morimoto C, Hori T, et al.: The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4 (+) T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans. Int Immunol 2009, 21:891-904.
• [11]Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF: Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 2009, 113:2451-60.
• [12]Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, et al.: Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993, 73:447-56.
• [13]van Lier RA, Borst J, Vroom TM, Klein H, Van MP, Zeijlemaker WP, et al.: Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol 1987, 139:1589-96.
• [14]van Gisbergen KP, Klarenbeek PL, Kragten NA, Unger PP, Nieuwenhuis MB, Wensveen FM, et al.: The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity 2011, 35:97-108.
• [15]Wensveen FM, Unger PP, Kragten NA, Derks IA, Ten BA, Arens R, et al.: CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load. J Immunol 2012, 188:4256-67.
• [16]Agematsu K, Kobata T, Sugita K, Freeman GJ, Beckmann MP, Schlossman SF, et al.: Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J Immunol 1994, 153:1421-9.
• [17]Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T, et al.: CD27-mediated activation of murine NK cells. J Immunol 2000, 164:1741-5.
• [18]Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, et al.: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002, 3:83-90.
• [19]Lens SM, Drillenburg P, Den Drijver BF, Van SG, Pals ST, Van Lier RA, et al.: Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999, 106:491-503.
• [20]Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, et al.: Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002, 62:2592-9.
• [21]Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF: CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012, 72:3664-3676.
• [22]Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al.: Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012, 18:432-41.
• [23]Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al.: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010, 49:40-51.
• [24]Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, et al.: Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 2010, 103:676-84.
• [25]Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J, et al.: Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005, 41:1794-801.
• [26]Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL: CD70 expression patterns in renal cell carcinoma. Hum Pathol 2012, 43:1394-9.
• [27]Park GB, Kim YS, Lee HK, Song H, Cho DH, Lee WJ, et al.: Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway. J Immunol 2010, 185:7274-84.
• [28]Penaloza-MacMaster P, Ur RA, Iyer SS, Yagita H, Blazar BR, Ahmed R: Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J Virol 2011, 85:6168-74.
• [29]Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, et al.: Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 2004, 199:1595-605.
• [30]Diegmann J, Junker K, Loncarevic IF, Michel S, Schimmel B, Von EF: Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006, 8:933-8.
• [31]Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF: Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med 2006, 203:2145-55.
• [32]Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC: Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012, 72:6119-29.
• [33]Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4 + CD25 T cells. Blood 2007, 110:2537-44.
• [34]Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, et al.: T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011, 117:4304-14.
• [35]McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, et al.: Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007, 109:1185-92.